Semaglutide vs Retatrutide
The established GLP-1 champion versus the triple-agonist challenger. How the next generation of weight loss therapy stacks up against the current standard.
| Feature | Semaglutide | Retatrutide |
|---|---|---|
| Brand Names | Ozempic, Wegovy, Rybelsus | LY3437943 (no brand yet) |
| Mechanism | GLP-1 agonist (single) | GLP-1/GIP/Glucagon (triple) |
| Max Weight Loss | ~15โ17% (Phase 3) | ~24% (Phase 2) |
| FDA Status | โ Approved | ๐ฌ Phase 3 |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Dosing | Weekly injection | Weekly injection |
| Available Now? | โ Yes, widely prescribed | โ Clinical trials only |
Mechanism of Action
Semaglutide: GLP-1 Single Agonist
Semaglutide activates GLP-1 receptors, which:
- Suppress appetite and reduce food intake via brain signaling
- Slow gastric emptying for prolonged satiety
- Enhance glucose-dependent insulin secretion
- Suppress glucagon release (lowering blood sugar)
This single-pathway approach has proven highly effective, with semaglutide becoming the most prescribed weight loss medication in history.
Retatrutide: GLP-1/GIP/Glucagon Triple Agonist
Retatrutide (LY3437943) activates three hormone receptors simultaneously:
- GLP-1: same appetite suppression and insulin effects as semaglutide
- GIP: enhanced insulin sensitivity and improved fat metabolism (same pathway added by tirzepatide)
- Glucagon: the third pathway โ increases energy expenditure, promotes hepatic fat oxidation, and drives thermogenesis
Why Glucagon Is the Key Differentiator
While GLP-1 and GIP reduce food intake, glucagon receptor activation increases energy output. This means retatrutide attacks obesity from both sides: less energy in (appetite suppression) AND more energy out (increased metabolic rate and fat burning). This is theoretically why it shows greater weight loss than single or dual agonists. It's the first approved-track molecule to combine all three pathways.
Efficacy: Weight Loss Data
The Numbers
Semaglutide (STEP 1, Phase 3): 14.9% mean body weight loss at 2.4 mg over 68 weeks. One-third of participants lost โฅ20%.
Retatrutide (Phase 2, 48 weeks): Up to 24.2% mean body weight loss at 12 mg dose. Over 90% of participants on the highest dose lost โฅ10%, and the weight loss curves had not plateaued at 48 weeks โ meaning the final number could be higher with longer treatment.
Key context: The retatrutide numbers above are from a Phase 2 trial (smaller sample, shorter duration). Phase 3 TRIUMPH-1 has since been published: 25.0% mean weight loss at 12 mg over 80 weeks versus 3.9% on placebo (NEJM 2026, PMID 42814954).
What "Not Plateaued" Means
Most weight loss drugs show a plateau: the weight loss curve flattens over time as the body adapts. In semaglutide trials, weight loss largely plateaued by week 60. Retatrutide's Phase 2 data showed the weight loss curve still declining at 48 weeks, suggesting the full potential hadn't been reached. If the Phase 3 trial (which runs longer) confirms this, retatrutide could achieve 25โ30% weight loss in some patients.
Approval Status & Availability
| Milestone | Semaglutide | Retatrutide |
|---|---|---|
| T2D Approval | 2017 (Ozempic) | Not yet (in trials) |
| Obesity Approval | 2021 (Wegovy) | Not yet (Phase 3) |
| Phase 3 Program | STEP (completed) | TRIUMPH (ongoing) |
| Est. Availability | Available now | Potentially 2027โ2028 |
| Oral Version | Rybelsus (oral tablet) | Unknown (injection only for now) |
Timeline Reality Check
Even with positive Phase 3 data, FDA review and approval takes time. Retatrutide's TRIUMPH program includes multiple trials for obesity, type 2 diabetes, and NASH/MASH. TRIUMPH-1 and TRIUMPH-2 were published in September 2026, but retatrutide is not FDA-approved and no approval date has been set, and delays are common in drug development. For patients who need treatment now, semaglutide and tirzepatide are available today.
Side Effect Profile
Based on available data (Phase 3 for semaglutide, Phase 2 for retatrutide):
| Side Effect | Semaglutide | Retatrutide |
|---|---|---|
| Nausea | ~44% | ~25โ45% (dose-dependent) |
| Diarrhea | ~30% | ~22โ35% |
| Vomiting | ~24% | ~10โ20% |
| Heart Rate | Slight increase | Slight increase (glucagon effect) |
| Discontinuation | ~7% due to AEs | ~6% in Phase 2 |
The glucagon component in retatrutide raises theoretical concerns about hyperglycemia, but this was not observed in trials; the GLP-1 and GIP pathways appear to counterbalance glucagon's glucose-raising effects effectively. Phase 3 data will provide a fuller safety picture.
The Verdict
- You need treatment today; it's FDA-approved and widely available
- You want a proven drug with years of real-world safety data
- You prefer an oral option (Rybelsus)
- Your insurance covers it (established coverage pathways)
- You've plateaued on current GLP-1 therapy and want the next evolution
- Maximum possible weight loss is your primary goal
- You're interested in the metabolic benefits of glucagon receptor activation
- You're already participating in or eligible for clinical trials
Retatrutide's Phase 2 data is the most impressive ever seen in obesity pharmacotherapy. The ~24% weight loss with curves still declining is exciting. But it's not available yet, and Phase 2 data doesn't always hold up in Phase 3. Semaglutide is proven, available, and effective right now. For those already on semaglutide or tirzepatide, retatrutide represents a potential future upgrade, not a reason to wait on treatment today. See also our retatrutide deep dive and clinical results page.
Frequently Asked Questions
In Phase 2 trials, retatrutide showed approximately 24% body weight loss at the highest dose over 48 weeks, compared to semaglutide's approximately 15โ17% in Phase 3 trials. Retatrutide is a triple agonist (GLP-1/GIP/glucagon) while semaglutide targets only GLP-1.
As of October 2026, retatrutide is not FDA-approved. Its Phase 3 TRIUMPH-1 and TRIUMPH-2 trials, run by Eli Lilly, were published in September 2026, and no approval date has been set.
A triple agonist activates three hormone receptors simultaneously. Retatrutide targets GLP-1 (appetite), GIP (metabolism), and glucagon (energy expenditure). This attacks obesity from multiple angles: reducing intake AND increasing output.
Both share GI side effects (nausea, diarrhea, vomiting) common to GLP-1 agonists. Retatrutide's side effects were manageable with dose titration in Phase 2. Phase 3 data will provide the full safety picture.
Retatrutide is not FDA-approved. Its Phase 3 TRIUMPH-1 and TRIUMPH-2 results were published in September 2026, but no approval date has been set, and regulatory timelines can shift. Semaglutide is available now.
Recommended Products
Supplies and tools our readers commonly look for
Affiliate links support HighPeptides at no extra cost.
Explore Peptide Tools
Calculate dosing and check interactions for GLP-1 medications